Consider Ethical Questions of 'Designer Babies'
By Elizabeth M. Meade,
The Morning Call
| 03. 10. 2014
A recent
New York Times article (Feb. 25) on a new fertility procedure that involves using the genetic material of three people to create a baby does a very good job of outlining the major ethical challenges posed by the technique.
The procedure is intended to produce children free of certain genetic defects, by replacing the mitochondria of the egg with the mitochondria of a donor who is free of the genetic defect. It could potentially be a godsend to families who risk passing certain catastrophic genetic defects on to their children. But, as The Times article rightly points out, it raises the ethical questions of whether we should be designing our children to be free of whatever we consider to be defects.
"Designer babies," as they are often called, represent both the best and worst of our understanding of parenthood. Several techniques already allow us to prevent passing genetic defects on to the next generation.
For years, fertility clinics have been able to screen embryos for genetic defects before implanting them; in some cases, halting or slowing the prevalence...
Related Articles
By Abby Vesoulis, Mother Jones | 04.18.2026
Two years ago, we devoted an entire issue to the rise of the American oligarchy. Since then, our oligarchic system has become more entrenched and pervasive, revolving around a small crew of tech titans whose quest for wealth and...
By Alex Aylward, Daniel J. Fairbanks, Maria Kiladi, and Gregory Radick , Heredity | 04.20.2026
Genetics and eugenics co-evolved at the beginning of the twentieth century and remained associated through the 1940s and beyond. Early geneticists were far from unanimous in their views on eugenics; some avidly supported the movement, whereas others openly opposed it...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...